Syntegon reports H1 2025 EBITDA higher by 41% to €127 million
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
Subscribe To Our Newsletter & Stay Updated